{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"CLRB","limit":50},"count":50,"signals":[{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"ary efficacy endpoints from the Part A dose-finding portion. The CLOVER-1 Phase 2b study, where iopofosine remains under further evaluation in highly refractory MM and CNSL patients, is closed to enrollment but ongoing with patients in follow-up. Fatalities have occurred in patients post-treatment with iopofosine. The CLOVER WaM study was designed as a pivotal registration study evaluating iopofosine","filed_date":"2026-03-04","accession":"0001104659-26-023167","full_text":"https://origin.rootz.global/static/filing/0001104659-26-023167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"not themselves be sufficiently insured or have a net worth sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material adverse effect on our business, prospects, financial condition and results of operations. Risks Related to Intellectual Property We expect to rely on our patents as well as specialized regulatory designations such","filed_date":"2026-03-04","accession":"0001104659-26-023167","full_text":"https://origin.rootz.global/static/filing/0001104659-26-023167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"s substantial risk. The occurrence of one or more of the events or circumstances described in the section entitled Risk Factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, cash flows, financial condition and results of operations. Important factors and risks that could cause actual results to differ materially from those in the forward-looking statemen","filed_date":"2025-10-20","accession":"0001104659-25-100854","full_text":"https://origin.rootz.global/static/filing/0001104659-25-100854.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"dy comparing the safety and efficacy of CLR125 in patients with advanced TNBC who are relapsed/refractory (r/r) to at least one prior therapy. Three dose levels will be assessed in parallel, with enrollment of patients in a 1:1:1 manner. We expect that each arm will have a minimum of 15 evaluable patients. CLR125 will be administered as a fractionated dose on Day 1 and Day 3 for cycle 1 and repeat ap","filed_date":"2025-06-30","accession":"0001104659-25-063849","full_text":"https://origin.rootz.global/static/filing/0001104659-25-063849.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ated by annual, quarterly and other reports and documents we file with the SEC after the date of this prospectus and that are incorporated by reference herein. Each of these risk factors could have a material adverse effect on our business, results of operations, financial position or cash flows, which may result in the loss of all or part of your investment. For more information, see Where You Can Find Additional Infor","filed_date":"2025-06-30","accession":"0001104659-25-063849","full_text":"https://origin.rootz.global/static/filing/0001104659-25-063849.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"split of our common stock at a ratio between 1:10 and 1:30, if and when determined by our Board of Directors (the Reverse Split Proposal); | | |  4. |  To hold a non-binding advisory vote to approve named executive officer compensation; | | |  5. |  To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve t","filed_date":"2025-04-28","accession":"0001104659-25-040241","full_text":"https://origin.rootz.global/static/filing/0001104659-25-040241.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"pofosine in WM patients that were r/r to at least two prior lines of therapy including having failed or had a suboptimal response to a Bruton tyrosine kinase inhibitor (BTKi). The study completed enrollment in the fourth quarter of 2023, and initial top line data from the study was reported in January 2024. CLOVER- 4 [Table of Contents](#TOC) WaM was a single-arm study with a target enrollment of 50","filed_date":"2025-03-13","accession":"0001410578-25-000329","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000329.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"not themselves be sufficiently insured or have a net worth sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material adverse effect on our business, prospects, financial condition and results of operations. Risks Related to Intellectual Property We expect to rely on our patents as well as specialized regulatory designations such","filed_date":"2025-03-13","accession":"0001410578-25-000329","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000329.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"pofosine in WM patients that were r/r to at least two prior lines of therapy including having failed or had a suboptimal response to a Bruton tyrosine kinase inhibitor (BTKi). The study completed enrollment in the fourth quarter of 2023, and initial top line data from the study was reported in January 2024. CLOVER-WaM was a single-arm study with a target enrollment of 50 patients. Topline safety data","filed_date":"2024-10-29","accession":"0001410578-24-001704","full_text":"https://origin.rootz.global/static/filing/0001410578-24-001704.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"or those of our suppliers. Accordingly, any conflict, military action, terrorist attack, natural disasters, public health crises or cyber-attack that impacts us or any of our suppliers, could have a material adverse effect on our business, liquidity, prospects, financial condition and results of operations. War, terrorism, other acts of violence, or natural or manmade disasters may affect the markets in which we operat","filed_date":"2024-10-29","accession":"0001410578-24-001704","full_text":"https://origin.rootz.global/static/filing/0001410578-24-001704.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; | | |  | 4. | To hold a non-binding advisory vote to approve named executive officer compensation; and | | |  | 5. | To transact such other business as may properly come before the Annual Meeting. | | Stockholders of record at the close of business on Wednesday, April 24, 2024 are en","filed_date":"2024-04-26","accession":"0001104659-24-053057","full_text":"https://origin.rootz.global/static/filing/0001104659-24-053057.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"pofosine in WM patients that were r/r to at least two prior lines of therapy including having failed or had a suboptimal response to a Bruton tyrosine kinase inhibitor (BTKi). The study completed enrollment in the fourth quarter of 2023, and initial top line data from the study was reported in January 2024. CLOVER-WaM was a single-arm study with a target enrollment of 50 patients. Topline safety data","filed_date":"2024-03-27","accession":"0001410578-24-000307","full_text":"https://origin.rootz.global/static/filing/0001410578-24-000307.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"or those of our suppliers. Accordingly, any conflict, military action, terrorist attack, natural disasters, public health crises or cyber-attack that impacts us or any of our suppliers, could have a material adverse effect on our business, liquidity, prospects, financial condition and results of operations. War, terrorism, other acts of violence, or natural or manmade disasters may affect the markets in which we operat","filed_date":"2024-03-27","accession":"0001410578-24-000307","full_text":"https://origin.rootz.global/static/filing/0001410578-24-000307.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"es* has the meaning set forth in Section 4.15(c)(i). *Lien* means any lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions of any kind. *Material Adverse Effect* means a material adverse effect on the results of operations, assets, prospects, business or financial condition of the Company and the Subsidiaries, taken as a whole, except that any of the followi","filed_date":"2023-09-08","accession":"0001104659-23-099368","full_text":"https://origin.rootz.global/static/filing/0001104659-23-099368.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023; | | |  | 4. | To hold a non-binding advisory vote to approve named executive officer compensation; and | | |  | 5. | To transact such other business as may properly come before the Annual Meeting. | | Stockholders of record at the close of business on Tuesday, April 25, 2023 are enti","filed_date":"2023-04-28","accession":"0001104659-23-052980","full_text":"https://origin.rootz.global/static/filing/0001104659-23-052980.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ic continues to rapidly evolve. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis could have a material negative impact on our business, financial condition and operating results. To the extent that COVID-19 pandemic impacts our business in any way, it may also have the effect of heightening the impact of other risk f","filed_date":"2023-03-09","accession":"0001410578-23-000224","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000224.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"etion, and the Compensation Committee has not determined future awards or who might receive them. For illustrative purposes, the following table shows the number of awards made under the 2021 Plan to named executive officers, current executive officers as a group, current directors who are not executive officers as a group, and all employees, including all current officers who are not executive officers, as a group, in","filed_date":"2022-04-29","accession":"0001104659-22-053571","full_text":"https://origin.rootz.global/static/filing/0001104659-22-053571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ic continues to rapidly evolve. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis could have a material negative impact on our  32 [Table of Contents](#TOC) business, financial condition and operating results. To the extent that COVID-19 pandemic impacts our business in any way, it may also have the effect of heighten","filed_date":"2022-03-21","accession":"0001410578-22-000436","full_text":"https://origin.rootz.global/static/filing/0001410578-22-000436.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"centive Plan (the 2021 Plan) reserving 6,000,000 shares for issuance under such plan and the material terms thereof; | | |  |  3. |  To approve on a non-binding advisory basis the compensation of our named executive officers; | | |  |  4. |  To hold a non-binding advisory vote on the frequency of future stockholder advisory votes on executive compensation; | | |  |  5. |  To ratify the appointment of Baker Tilly US, LLP","filed_date":"2021-05-13","accession":"0001104659-21-065536","full_text":"https://origin.rootz.global/static/filing/0001104659-21-065536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ic continues to rapidly evolve. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis could have a material negative impact on our business, financial condition and operating results. To the extent that COVID-19 pandemic impacts our business in any way, it may also have the effect of heightening the impact of other risk f","filed_date":"2021-03-02","accession":"0001104659-21-030445","full_text":"https://origin.rootz.global/static/filing/0001104659-21-030445.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"not themselves be sufficiently insured or have a net worth sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material adverse effect on our business, prospects, financial condition and results of operations. **Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will prevent or delay","filed_date":"2020-03-09","accession":"0001104659-20-030742","full_text":"https://origin.rootz.global/static/filing/0001104659-20-030742.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"k available for issuance under our Amended and Restated 2015 Stock Incentive Plan (the 2015 Plan) by 700,000 shares; | | |  |  3. |  To approve on a non-binding advisory basis the compensation of our named executive officers; | | |  |  4. |  To ratify the appointment of Baker Tilly Virchow Krause, LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019; and | | |  |","filed_date":"2019-04-29","accession":"0001144204-19-021924","full_text":"https://origin.rootz.global/static/filing/0001144204-19-021924.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"FDA. On November 8, 2018, the FDA notified us that CLR 131 would be exempted from the Import Alert placed on CPDC in relation to our ongoing clinical studies. As a result, we have resumed patient enrollment in our CLR 131 hematology clinical studies. We await either the lifting of the Import Alert or the granting of an exemption from the FDA for any future shipments into the U.S. in connection with o","filed_date":"2019-02-26","accession":"0001144204-19-009973","full_text":"https://origin.rootz.global/static/filing/0001144204-19-009973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $1.87375, subject to a","filed_date":"2017-10-11","accession":"0001144204-17-052049","full_text":"https://origin.rootz.global/static/filing/0001144204-17-052049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"the number of shares of common stock available for issuance under our 2015 Stock Incentive Plan by 1,200,000 shares; | | |  |  3. |  To approve on a non-binding advisory basis the compensation of our named executive officers; | | |  |  4. |  To ratify the appointment of our independent registered public accounting firm for the year ending December 31, 2017; | | |  |  5. |  To vote on an amendment to our certificate of i","filed_date":"2017-04-25","accession":"0001144204-17-021971","full_text":"https://origin.rootz.global/static/filing/0001144204-17-021971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"Recommendation** The Class II director must be elected by a plurality of the votes properly cast at the Special Meeting. This means that the nominee receiving the highest number of FOR votes will be elected as a Class II director. Votes may be cast FOR or WITHHELD FROM the nominee. Votes that are WITHHELD FROM the nominee will be excluded entirely from the vote and will have no effect. ** ** **Our Board of Directors recommend","filed_date":"2016-06-01","accession":"0001144204-16-106294","full_text":"https://origin.rootz.global/static/filing/0001144204-16-106294.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $2.20, subject to adju","filed_date":"2015-09-30","accession":"0001144204-15-057373","full_text":"https://origin.rootz.global/static/filing/0001144204-15-057373.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"luding the reservation of 700,000 shares of common stock for issuance thereunder; | | |  | 4. | To consider and vote upon a non-binding advisory say on pay proposal to approve the compensation of our named executive officers; | | |  | 5. | To consider and vote upon a non-binding advisory say on frequency proposal on the frequency of future stockholder advisory votes on executive compensation; | | |  | 6. | To consider a","filed_date":"2015-04-22","accession":"0001144204-15-024239","full_text":"https://origin.rootz.global/static/filing/0001144204-15-024239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"of tumors and metastases in a broad range of cancers. Investigator-sponsored Phase 1/2 clinical trials of I-124-CLR1404 are ongoing across 11 solid tumor indications. In March 2014, we commenced enrollment in a Phase 2 clinical trial studying I-124-CLR1404 in the imaging of glioblastoma, a type of glioma. We contemplate completing this trial during 2015. In April 2014, the U.S. Food and Drug Adminis","filed_date":"2015-03-24","accession":"0001144204-15-017897","full_text":"https://origin.rootz.global/static/filing/0001144204-15-017897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"of tumors and metastases in a broad range of cancers. Investigator-sponsored Phase 1/2 clinical trials of I-124-CLR1404 are ongoing across 11 solid tumor indications. In March 2014, we commenced enrollment in a Phase 2 clinical trial studying I-124-CLR1404 in the imaging of glioblastoma. We expect to complete this trial by the end of 2014, subject to additional funding. |  | **** |  |  |  I-131-CLR1","filed_date":"2014-03-19","accession":"0001144204-14-016712","full_text":"https://origin.rootz.global/static/filing/0001144204-14-016712.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"|  |  | |  Stock options |  |  |  12,693,166 |  |  |  6,439,188 |  |  |  12,693,166 |  |  | **12. COMMITMENTS** **Consulting and Employment Agreements** **** On October 4, 2013, Dr. Simon Pedder was appointed as Acting Chief Executive Officer and elected as a Class III Director replacing Harry Palmin. The Company entered into a consulting agreement with Dr. Pedder for the period from October 4, 2013 through March 31, 2014 under which the","filed_date":"2014-03-19","accession":"0001144204-14-016712","full_text":"https://origin.rootz.global/static/filing/0001144204-14-016712.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"cumentation). **Investment Amount** means an amount equal to $2,000,000.00. **License Agreements** has the meaning set forth in Section 4.14(b). **Losses** has the meaning set forth in Section 8.2. **Material Adverse Effect** means a material adverse effect on (i) the assets and liabilities, prospects, results of operations, condition (financial or otherwise) or business of the Company, or (ii) the ability of the Compan","filed_date":"2012-11-06","accession":"0001144204-12-059778","full_text":"https://origin.rootz.global/static/filing/0001144204-12-059778.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"comes. While we have commenced dosing in our CLOVER-WaM pivotal clinical study of iopofosine in Waldenstroms macroglobulinemia (WM), we have experienced material delays in patient recruitment and enrollment as a result of continued resourcing issues related to COVID-19 at study sites and potentially resulting from concerns among patients about participating in clinical studies during a public health","filed_date":"2023-03-09","accession":"0001410578-23-000224","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000224.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"comes. While we have commenced dosing in our CLOVER-WaM pivotal clinical study of iopofosine in Waldenstroms macroglobulinemia (WM), we have experienced material delays in patient recruitment and enrollment as a result of continued resourcing issues related to COVID-19 at study sites and potentially resulting from concerns among patients about participating in clinical studies during a public health","filed_date":"2022-03-21","accession":"0001410578-22-000436","full_text":"https://origin.rootz.global/static/filing/0001410578-22-000436.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"must be elected by a plurality of the votes properly cast at the Annual Meeting. Votes may be cast FOR or WITHHELD from the nominees and the nominees receiving the highest number of FOR votes will be elected as Class I directors. Votes that are WITHHELD from a nominee will not be counted and will have no effect. **Our Board of Directors recommends that you vote FOR the election of Stephen A. Hill and John Neis.** | | 4 | |","filed_date":"2018-04-23","accession":"0001144204-18-021824","full_text":"https://origin.rootz.global/static/filing/0001144204-18-021824.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"e announced performance results from the first patient cohort in January of 2016. The studys Data Monitoring Committee (DMC), unanimously agreed to advance CLR 131 into the second cohort. Patient enrollment is currently ongoing and the company plans to provide a study update in the third quarter of 2016. The primary goals of the Phase 1 study are to assess the compounds safety, identify the optimal P","filed_date":"2016-03-11","accession":"0001144204-16-087438","full_text":"https://origin.rootz.global/static/filing/0001144204-16-087438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":88,"match_count":11,"context":"be elected by a plurality of the votes properly cast at the Annual Meeting. Votes may be cast FOR or WITHHELD from the nominees and the two nominees receiving the highest number of FOR votes will be elected as Class III directors. Votes that are WITHHELD from a nominee will not be counted and will have no effect. ** ** **Our Board of Directors recommends that you vote FOR the election of Dr. Loren and Mr. Swirsky.** ** ** |","filed_date":"2020-04-28","accession":"0001104659-20-052421","full_text":"https://origin.rootz.global/static/filing/0001104659-20-052421.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"refractory multiple myeloma and a range of other B-cell malignancies, and its Phase 1 clinical study for relapsed or refractory multiple myeloma. As a result, the Company plans to resume patient enrollment in those clinical studies. The Company awaits authorization from the FDA for any future shipments in connection with its Phase 1 study of pediatric patients with neuroblastoma, sarcomas, lymphomas","filed_date":"2018-11-13","accession":"0001144204-18-059004","full_text":"https://origin.rootz.global/static/filing/0001144204-18-059004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"dy comparing the safety and efficacy of CLR125 in patients with advanced TNBC who are relapsed/refractory (r/r) to at least one prior therapy. Three dose levels will be assessed in parallel, with enrollment of patients in a 1:1:1 manner. We expect that each arm will have a minimum of 15 evaluable patients. CLR125 will be administered as a fractionated dose on Day 1 and Day 3 for cycle 1 and repeat ap","filed_date":"2025-11-13","accession":"0001104659-25-110827","full_text":"https://origin.rootz.global/static/filing/0001104659-25-110827.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"yable at the time of termination) and (iii) 24 months of payment or reimbursement of health insurance (equal to the premium paid by the Company prior to the date of termination), each payable in installments over 24 months. Following a termination of employment by the Company without cause or by Mr. Caruso for good reason that is not within 12 months after a change in control, Mr. Caruso is entitled","filed_date":"2022-04-29","accession":"0001104659-22-053571","full_text":"https://origin.rootz.global/static/filing/0001104659-22-053571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"get bonus payable over 18 months (a total of 1.5x the annual target bonus payable at the time of termination) and (iii) 18 months of payment or reimbursement of health insurance, each payable in installments over 18 months following a termination of employment by the Company without cause or by Mr. Caruso for good reason, and contingent upon the execution of a release agreement in favor of the Compan","filed_date":"2021-05-13","accession":"0001104659-21-065536","full_text":"https://origin.rootz.global/static/filing/0001104659-21-065536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"Each warrant tranche has a Mandatory Exercise Milestone. For the Tranche A Warrants the Mandatory Exercise Milestone is the initiation of the Randomized Confirmatory Phase 3 Study, defined as the enrollment of the first patient in the study. For the Tranche B Warrants the Mandatory Exercise Milestone is the acceptance for review of the New Drug Application by the U.S. Food and Drug Administration (FD","filed_date":"2026-08-13","accession":"0001104659-26-095426","full_text":"https://origin.rootz.global/static/filing/0001104659-26-095426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":79,"match_count":8,"context":"ensation Committee considers various matters relevant to the development of a reasonable and prudent compensation program, including whether the policies and practices are reasonably likely to have a material adverse effect on us. We believe that the mix and design of our executive compensation plans and policies do not encourage management to assume excessive risks and are not reasonably likely to have a material adver","filed_date":"2025-04-28","accession":"0001104659-25-040241","full_text":"https://origin.rootz.global/static/filing/0001104659-25-040241.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":79,"match_count":8,"context":"not themselves be sufficiently insured or have a net worth sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material adverse effect on our business, prospects, financial condition and results of operations. **Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will prevent or delay","filed_date":"2019-02-26","accession":"0001144204-19-009973","full_text":"https://origin.rootz.global/static/filing/0001144204-19-009973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":74,"match_count":8,"context":"not themselves be sufficiently insured or have a net worth sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material adverse effect on our business, prospects, financial condition, and results of operations. ** ** **Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will prevent or","filed_date":"2018-03-21","accession":"0001144204-18-016175","full_text":"https://origin.rootz.global/static/filing/0001144204-18-016175.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"dy comparing the safety and efficacy of CLR125 in patients with advanced TNBC who are relapsed/refractory (r/r) to at least one prior therapy. Three dose levels will be assessed in parallel, with enrollment of patients in a 1:1:1 manner. We expect that each arm will have a minimum of 15 evaluable patients. CLR125 will be administered as a fractionated dose on Day 1 and Day 3 for cycle 1 and repeat ap","filed_date":"2025-08-14","accession":"0001410578-25-001778","full_text":"https://origin.rootz.global/static/filing/0001410578-25-001778.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"get bonus payable over 18 months (a total of 1.5x the annual target bonus payable at the time of termination) and (iii) 18 months of payment or reimbursement of health insurance, each payable in installments over 18 months. | | |  | | No Change in Control. If Mr. Caruso is otherwise terminated other than for cause or for good reason, Mr. Caruso would be entitled to severance in an amount equal to 12","filed_date":"2020-04-28","accession":"0001104659-20-052421","full_text":"https://origin.rootz.global/static/filing/0001104659-20-052421.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"e announced that we had successfully completed the second cohort in this Phase 1b dose-escalation trial. The second two-patient cohort was successfully dosed with 25 mCi/m2 of CLR 131, triggering enrollment into the third cohort at 37.5 mCi/m2. Data from the second cohort indicated CLR 131 was well-tolerated, without any dose limiting or sub-dose limiting toxicities, enabling enrollment of the third","filed_date":"2017-03-15","accession":"0001144204-17-014611","full_text":"https://origin.rootz.global/static/filing/0001144204-17-014611.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":72,"match_count":9,"context":"00,000 related to the termination in 2013 of the external Business Development relationship with Extera. These reductions were partially offset by an increase in legal fees of approximately $94,000. *Restructuring Costs.* The Company recorded approximately $222,000 for restructuring costs in 2014, as compared to $1,097,000 in 2013. These expenses related primarily to the restructuring of the Companys management duri","filed_date":"2015-03-24","accession":"0001144204-15-017897","full_text":"https://origin.rootz.global/static/filing/0001144204-15-017897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CLRB","company":"Cellectar Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":66,"match_count":7,"context":"d accrued liabilities to UW of approximately $40,000 and $353,000 as of December 31, 2015 and 2014, respectively. **16. RESTRUCTURING COSTS AND OTHER CORPORATE CHANGES** On June 15, 2015, the Company appointed a new President and Chief Executive Officer, who was also named to the Companys Board as a Class II director. The former President, Chief Executive Officer and Class II director retired from each of those positions. In additi","filed_date":"2016-03-11","accession":"0001144204-16-087438","full_text":"https://origin.rootz.global/static/filing/0001144204-16-087438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"fe5ed7ed623a9c7d83801a110ad79f4a434e25e1f8eff2b6f0936e31e1a68074","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"54c02ff0615e71b1e32a23d8ee5e7e5fc2ae2f5b1a6419c7ad600f61029fc496","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":97,"hourly_limit":500,"remaining":403,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}